Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma

European Journal of Gynaecological Oncology

Volumn 30, Issue 2, 2009, Pages 142-144

  Zucchi, F ^a,d   da Silva, I D C G ^a   Ribalta, J C L ^a   de Souza, N C N ^a   de Gois Speck N M ^a   Girao M J B C ^a   Brenna, S M F ^b   Syrjanen K J ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d NONE   (Brazil)

Author keywords

Apoptosis; Cervical cancer; Fas; Human papillomavirus; Polymorphism; Risk factor

Indexed keywords

ADENINE; FAS ANTIGEN; GUANINE;

ADULT; APOPTOSIS; ARTICLE; BRAZIL; CASE CONTROL STUDY; COLPOSCOPY; CONTROLLED STUDY; DNA CONTENT; DNA POLYMORPHISM; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUTANT; POLYMERASE CHAIN REACTION; PROMOTER REGION; TRANSCRIPTION REGULATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; WILD TYPE;

ADULT; ANTIGENS, CD95; APOPTOSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECEPTORS, DEATH DOMAIN; UTERINE CERVICAL NEOPLASMS;

EID: 65349122408     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Thompson C.B.: "Apoptosis in the pathogenesis and treatment of disease". Science, 1995, 10, 1456.
2. Evan G.I., Vousden K.H.: "Proliferation, cell cycle and apoptosis in cancer". Nature, 2001, 17, 342.
3. Lowe S.W., Lin A.W.: "Apoptosis in cancer". Carcinogenesis, 2000, 21, 485.
4. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M. et al.: "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis". Cell, 1991, 66, 233.
5. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W. et al.: "Monoclonal antibody-mediated tumor regression by induction of apoptosis". Science, 1989, 245, 301.
6. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C. et al.: "Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen". J. Biol. Chem., 1992, 267, 10709.
7. Suda T., Takahashi T., Golstein P., Nagata S.: "Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family". Cell, 1993, 75, 1169.
8. Reichmann E.: "The biological role of the Fas/FasL system during tumor formation and progression". Semin. Cancer Biol., 2002, 12, 309.
9. Nagata S., Golstein P.: "The Fas death factor". Science, 1995, 267, 1449.
10. Muschen M., Warskulat U., Beckmann M.W.: "Defining CD95 as a tumor suppressor gene". J. Mol. Med., 2000, 78, 312.
11. Davidson W.F., Giese T., Fredrickson T.N.: "Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions". J. Exp. Med., 1998, 787, 1825.
12. Peter A.M., Kohfink B., Martin H., Griesinger F., Wormann B., Gahr M. et al.: "Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease". Exp. Hematol., 1999, 27, 868.
13. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Dong S.M., Pi J.H. et al.: "Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder". Cancer Res., 1999, 27, 3068.
14. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Kim S.H., Han J.Y. et al.: "Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer". Oncogene, 1999, 18, 3754.
15. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T. et al.: "Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand". Cell, 1994, 76, 969.
16. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K. et al.: "The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma". J. Immunol., 1998, 160, 5669.
17. Gartas C., Tohmoa Y., Barnas C., Taniere P., Hainaut P., Ohgaki H.: "Upregulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer". Cancer Res., 1998, 58, 2057.
18. Kase S., Osaki M., Adachi H., Tsujitani S., Kaibara N., Ito H.: "Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas". Int. J. Oncol., 2002, 20, 291.
19. Shibakita M., Tachibana M., Dhar D.K., Kotoh T., Kinugasa S., Kubota H. et al.: "Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer". Clin. Cancer Res., 1999, 5, 2464.
20. Huang Q.R., Morris D., Manolios N.: "Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene". Mol. Immunol., 1997, 34, 577.
21. Sibley K., Rollinson S., Allan J.M., Smith A.G., Law G.R., Roddam P.L. et al.: "Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia". Cancer Res., 2003, 63, 4327.
22. Kanemitsu S., Ihara K., Saifddin A., Otsuka T., Takeuchi T., Nagayama J. et al.: "A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus". J. Rheumatol., 2002, 29, 1183.
23. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C. et al.: "A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients". J. Immunol., 2003, 170, 132.
24. Song C.Y., Xing D.Y., Tan W., Wei Q., Lin D.X.: "Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population". Cancer Res., 2001, 61, 3272.
25. Sobin L.H., Wittekind C. (eds.). TNM Classification of Malignant Tumors. 5th edition, New York, Wiley-Leiss, 1997.
26. Kleinbaum D.G., Kupper L.L., Morgenstern H. (eds.). Epidemiologic Research: Principles and Quantitative Methods. London, Lifetime Learning Publications, 1982.
27. Gao Y.T., Mclaughlin J.K., Blot W.J., Ji B.T., Benichou J., Dai Q., et al.: "Risk factor for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking". Int. J. Cancer, 1994, 58, 192.
28. Suzuki N., Wakisaka S., Takeba Y, Mihara S., Sakane T.: "Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes". Cell Immunol., 1999, 25, 48.
29. Bijl M., Horst G., Limburg P.C., Kallenberg C.G.: "Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes". Eur. J. Clin. Invest., 2001, 31, 550.
30. Pugh B.F., Tjian R.: "Mechanism of transcriptional activation by Sp1: evidence for coactivators". Cell, 1995, 61, 1187.
31. Wang L.E., Cheng L., Spitz M.R., Wei Q.: "Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer". Lung Cancer, 2003, 42, 1.
32. Lai H.C., Sytwu H.K., Sun C.A., Yu M.H., Yu C.P., Liu H.S. et al.: "Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis". Int. J. Cancer, 2003, 103, 221.